Background: Celiac disease (CD) is an autoimmune disorder characterized by damage to the intestinal mucosa and nutrient malabsorption in severe cases. However, it remains unclear whether nutrient deficiencies and other adverse health effects are prevalent in individuals with positive CD serology identified through screening studies. Objective: The objective was to determine whether biomarkers of cardiometabolic health and nutritional status differ between those with positive and negative CD serology identified in a screening study of Canadian adults. Methods: Participants (n¼2832) were from the Toronto Nutrigenomics and Health Study and the Toronto Healthy Diet Study. Individuals were screened for CD-specific anti-tissue transglutaminase autoantibodies. Lipid profiles as well as concentrations of six carotenoids (a-carotene, b-carotene, b-cryptoxanthin, lutein, lycopene, and zeaxanthin), three tocopherols (a-tocopherol, d-tocopherol, and g-tocopherol), retinol, ascorbic acid, and 25-hydroxyvitamin D were cross-sectionally compared between those with positive and negative CD serology using general linear mixed models. Results: Individuals with positive CD serology (n¼23) had significantly lower levels of HDL-cholesterol (p¼0.008) and apolipoprotein-AI (p¼0.02), a higher ratio of total cholesterol to HDL-cholesterol (p¼0.006), and a higher apolipoprotein-B/AI ratio (p¼0.03) than those with negative CD serology. Positive CD serology was also associated with significantly lower concentrations of retinol (p¼0.006) in fully adjusted models. Those with positive CD serology had lower serum 25-hydroxyvitamin D in unadjusted models (p¼0.01), but not in fully adjusted models (p¼0.08). Conclusions: Individuals with undiagnosed CD may have unfavorable lipid profiles and be at elevated risk for inadequacy of certain fat-soluble vitamins, but not widespread nutrient deficiencies.
Introduction
Celiac disease (CD) is an autoimmune disorder that affects approximately 1% of individuals in North America and Europe (Kim et al., 2016; Mardini et al., 2015; Mustalahti et al., 2010) . Individuals with CD experience adverse autoimmune reactions to dietary intake of gluten, a protein found in wheat, barley, and rye, and strict adherence to a gluten-free diet remains the only available treatment to date (Green and Cellier, 2007) . Recent studies have suggested that the prevalence of CD is on the rise (Ludvigsson et al., 2013b; Rubio-Tapia et al., 2009) ; however, the underlying reasons for this increase are unclear. Predisposing variants in the human leukocyte antigen (HLA)-DQ region are necessary, but not sufficient for the development of CD (Dieli-Crimi et al., 2015) . Other risk factors associated with the development of CD include non-HLA genetic risk variants, early viral infections, and the composition of the gut microbiota (Sarno et al., 2015) .
CD has various clinical manifestations and levels of severity (Ludvigsson et al., 2013a) . The 'classical' presentation of CD is characterized by the development of autoantibodies against tissue transglutaminase (tTG), a high degree of villous atrophy, malabsorption and classical gastrointestinal symptoms, including diarrhea, steatorrhea, and weight loss. Failure to thrive is an indicator for classical CD, and this form is most commonly diagnosed in early childhood (Guandalini and Assiri, 2014) . 'Non-classical' CD is characterized by the presence of elevated tTG antibodies, no symptoms of malabsorption, but the potential presence of other gastrointestinal and extra-intestinal manifestations. This presentation of CD is often associated with a lower degree of damage to the intestinal mucosa and is most frequently diagnosed in adulthood (Guandalini and Assiri, 2014; Gujral et al., 2012) . Adults with positive CD serology and mild intestinal damage may also be relatively asymptomatic. This is referred to as the 'subclinical' form of CD (Fasano and Catassi, 2001; Guandalini and Assiri, 2014) . 'Potential' CD is characterized by the potential presence of CD autoimmunity, but no observable damage to the intestinal mucosa (Guandalini and Assiri, 2014; Gujral et al., 2012) . Finally, refractory CD is a rare and extremely severe form of CD where intestinal damage and symptoms of CD fail to improve on a gluten-free diet (Rubio-Tapia and Murray, 2010) .
Untreated CD is known to be associated with an increased risk of many adverse health outcomes related to impaired nutritional status. This is not surprising considering that damage to the intestinal mucosa and malabsorption are major hallmarks of the disorder. Studies of recently diagnosed CD patients have reported deficiencies in several vitamins and minerals compared with healthy controls (Botero-Lopez et al., 2011; Dahele and Ghosh, 2001; Wierdsma et al., 2013) . Individuals with newly diagnosed CD have also been shown to have altered blood lipid profiles compared with healthy controls (Brar et al., 2006; Capristo et al., 2000) . However, it is unclear whether such nutrient deficiencies and other adverse health effects associated with diagnosed CD are present in individuals not diagnosed with CD, but who test positive for CDassociated antibodies in screening studies. This is especially important considering that up to 85% of individuals with CD may be undiagnosed (Rubio-Tapia et al., 2012) . The objective of this study was to compare various biomarkers of cardiometabolic health and nutritional status in individuals with positive CD serology and those without such antibodies in a population of Canadian adults.
Methods

Study population
Participants were Canadian adults from two study populations described previously (Jamnik et al., 2017) . The Toronto Nutrigenomics and Health (TNH) Study is a cross-sectional examination of young adults aged 20-29 years recruited from the University of Toronto Campus (n¼1620). The Toronto Healthy Diet (THD) Study is a randomized-controlled trial (clinicaltrials.gov registration: NCT00516620), which investigated the effectiveness of various types of dietary interventions on weight loss and biomarkers of chronic disease (n¼1212 at baseline). Individuals in the THD Study were between 18 and 82 years of age, and all subjects came from households in the Toronto region with at least one member possessing a body mass index (BMI) 25 kg/m 2 . In both study populations, individuals had anthropometric measurements taken, provided a fasting blood sample for biomarker assessment, and completed the Toronto-modified Willet 196-item semi-quantitative food frequency questionnaire (FFQ). Subjects provided a self-reported account of their ethnocultural background and were placed into one of five groups: Caucasian, East Asian, South Asian, Other, or Unknown, as described previously (Garcia-Bailo et al., 2012) . Ethnocultural status was considered to be a potential confounder and was adjusted for in all analyses, since the prevalence of CD is known to vary by ethnicity (Gujral et al., 2012) . Details on subject exclusions and the number of individuals included in each analysis presented can be found in Figure 1 .
Celiac disease serology assessment
Serological screening for CD was carried out by measuring tTG autoantibodies as described previously (Jamnik et al., 2017) . Briefly, plasma samples from individuals possessing the HLA DQ2 and DQ8 risk variants necessary for the development of CD were screened initially using a dualisotope (IgAþIgG) anti-tTG ELISA (product no ORG540 S; Orgentec Diagnostika, Main, Germany). Screening for HLA DQ2 and DQ8 risk alleles in the entire population was performed by genotyping six single nucleotide polymorphisms in the HLA region (rs7454108, rs2395182, rs7775228, rs4713586, rs2187668, and rs4639334) as described previously (Jamnik et al., 2017; Monsuur et al., 2008) . Individuals who tested positive for tTG antibodies (15 U/ml) on this initial assay were then tested using a separate tTG IgA assay (product no ORG540A, Orgentec Diagnostika). Individuals who tested positive for anti-tTG IgA antibodies (10 U/ml) were considered to have positive CD serology. Individuals who tested negative for tTG IgA antibodies were screened for selective IgA deficiency using ELISA (product no CSB-E07985 h, Cusabio Biotech, Wuhan, China). Individuals identified as being IgA deficient (total IgA <7 mg/dl) were then screened using a separate assay for tTG IgG antibodies (product no ORG540G; Orgentec Diagnostika). Those with IgA deficiency and positive tTG IgG antibodies (10 U/ml) were considered to have positive CD serology. Those who were positive on the initial dual-isotope screen, but tTG IgA negative and IgA sufficient were considered to have equivocal serology and were excluded from the present study (n¼23). Those with a self-reported diagnosis of CD and negative serology were also excluded (n¼2). Individuals who did not have the HLA-DQ2/8 variants necessary for the development of CD were not screened for tTG antibodies, and were all considered to have negative CD serology in the present study. East Asian (n¼613) and South Asian (n¼220) individuals were excluded from all analyses in the present study due to the absence of individuals in these groups with positive CD serology. Analyses were, therefore, restricted to individuals of Caucasian or 'non-Caucasian' (Other or Unknown) ancestry.
Biomarker assessment
Markers of cardiometabolic health included triglycerides, total cholesterol, HDL-cholesterol, LDL-cholesterol, the ratio of total to HDL-cholesterol, apolipoprotein-AI (apo-AI), apolipoprotein-B (apo-B) and the ratio of apo-B to apo-AI. Biomarkers of nutritional status included serum carotenoids (a-carotene, b-carotene, b-cryptoxanthin, lutein, all-trans lycopene, and zeaxanthin), tocopherols (a-tocopherol, d-tocopherol, and g-tocopherol) , vitamin A (all-trans retinol), vitamin C (ascorbic acid), and vitamin D (25-hydroxyvitamin D (25OHD)). Participants with incomplete biomarker data were excluded from their respective analyses (see Figure 1 ).
Fasting blood samples were collected from each participant for biomarker assessment. Serum cholesterol (total, HDL, and LDL) and triglycerides were assessed using a chromatographic enzymatic method described previously (Cahill et al., 2009 ). Apo-AI and apo-B concentrations were measured at the University of Victoria-Genome British Columbia Proteomics Centre using a multiple reaction monitoring assay described previously (Domanski et al., 2012; Kuzyk et al., 2009 ). Biomarkers of nutritional status were only available for individuals from the TNH Study. Concentrations of all six carotenoids, three tocopherols and all-trans retinol were measured from plasma samples using reverse-phase isocratic HPLC with fluorescent detection as described previously (Liu et al., 2011) . Serum ascorbic acid was measured using HPLC as described previously (Cahill et al., 2009) . Circulating concentrations of 25OHD were measured using an HPLCtandem mass spectrometry assay as described elsewhere (Garcia-Bailo et al., 2013; Wagner et al., 2011) . Vitamin D values reported in the present study represent the sum of both 25-hydroxycholecalciferol (25-hydroxyvitamin D3) and 25-hydroxyergocalciferol (25-hydroxyvitamin D2).
Statistical analysis
All statistical analyses were performed using Statistical Analysis Software (SAS) version 9.2 (SAS Institute Inc., Cary, N.C., USA). Continuous variables were log e -or square root-transformed to improve normality when required. Raw means and measures of variance are reported in order to facilitate interpretability, but reported p-values are from models that use transformed variables where necessary. For all analyses, the a-error was set to 0.05 and reported p-values are 2-sided. When means were cross-sectionally compared between individuals with positive and negative CD serology, general linear mixed models (GLMM) were used in order to estimate variances separately between the two groups. The Satterthwaite approximation was used to adjust the degrees of freedom for the unequal variances. This was done to account for potentially heterogeneous variances that can arise between groups of contrasting sample sizes.
Subject characteristics were compared between those with positive and negative CD serology using GLMMs adjusted for age, sex, BMI, ethnicity and study population (TNH or THD Study) for continuous variables, and Fisher's exact test for categorical variables. Lipid profiles were compared between groups using GLMMs adjusted for age, sex, BMI, ethnicity and study population. Differences in circulating concentrations of nutritional biomarkers between groups were also compared using GLMMs. Only Caucasians from the TNH Study were included in the analysis of nutritional biomarkers as all individuals with positive CD serology and complete data on nutritional biomarkers were of Caucasian descent. All other analyses reported included individuals of non-Caucasian ethnicity. Biomarkers of nutritional status were not available for participants of the THD Study. Initially, the association between each nutritional biomarker and CD serology status was explored using unadjusted GLMMs (Model 1). Model 2 consisted of GLMMs adjusted for age, sex and BMI. Finally, Model 3 included the same covariates as Model 2 plus dietary intake of each respective compound derived from subjects' FFQ responses. This was done to identify differences between groups that were likely due to altered absorption of such nutritional biomarkers, rather than differences in dietary intake. Model 3 for retinol was further adjusted for serum triglycerides. For 25OHD, season of blood draw, physical activity and hormonal contraceptive use among women were also included in Model 3 since seasonal variation, sun exposure and hormonal contraceptives have been shown to significantly influence circulating levels of 25OHD (Garcia-Bailo et al., 2013) . Since outcome variables were selected based on an a priori hypothesis that undiagnosed CD may be associated with altered levels of these biomarkers, analyses were not adjusted for multiple comparisons. Furthermore, since many of the biomarkers assessed are highly correlated, accounting for multiple testing by treating these as independent tests would lead to an inflated type II error rate.
Results
A total of 23 participants with positive CD serology and no self-reported CD diagnosis were identified (Jamnik et al., 2017) . Participant characteristics for those with positive and negative CD serology are shown in Table 1 . There were no significant differences for any participant characteristics, including height, weight and BMI, between groups (p>0.05). Differences in blood lipid profiles between groups are shown in Table 2 . Individuals with positive CD serology had lower levels of HDL-cholesterol and a higher total to HDL-cholesterol ratio than those with negative CD serology (p<0.05). Circulating levels of apo-AI were also significantly lower, and the ratio of apo-B to apo-AI was higher in those with positive CD serology (p<0.05). Such differences were driven by HDL-cholesterol and apo-AI since total cholesterol, LDL-cholesterol, serum triglycerides, and apo-B did not significantly differ between those with positive and negative CD serology. Table 3 shows the association between various biomarkers of nutritional status and CD serology status. Individuals with positive CD serology had significantly (p<0.05) lower levels of circulating retinol than those with negative CD serology in all models. Positive CD serology was associated with lower levels of 25OHD in the unadjusted model (p¼0.01) and after adjusting for age, sex, and BMI (p¼0.01); however, this association was no longer significant after adjusting further for vitamin D intake, season of blood draw, physical activity, and hormonal contraceptive use among women (p¼0.08). No other differences in circulating markers of nutritional status between those with positive and negative CD serology were identified in any models (p>0.05). None of the 23 individuals with positive CD serology were smokers, and additional adjustment for smoking status did not materially alter any of the identified associations.
Discussion
Severe manifestations of CD are known to be associated with failure to thrive, unexplained weight loss and various signs of malnutrition (Guandalini and Assiri, 2014) ; however, it is unclear whether individuals with undiagnosed CD are affected by similar adverse health effects. The objective of this study was to examine the association between positive CD serology in those without a diagnosis of CD and various biomarkers of cardiometabolic health and nutritional status. We found that individuals with positive CD serology had lower levels of HDL-cholesterol, lower apo-AI, a higher total to HDL-cholesterol ratio, a higher apo-B/AI ratio, and lower levels of circulating retinol compared with individuals with negative CD serology.
Positive CD serology was not associated with any differences in height, weight, or BMI compared to those with negative CD serology in our study population. It is well established that severe manifestations of CD, particularly those diagnosed in early childhood, are associated with reduced height and body weight due to the sustained presence of severe intestinal damage and resulting nutrient malabsorption (Tully, 2008) . However, recent studies have found that this classical presentation of CD may not be applicable to all cases, particularly to those that are diagnosed in adulthood (Dickey and Kearney, 2006; Tucker et al., 2012) . Indeed, in the United States, almost 40% of those with biopsy-proven CD have been shown to be overweight or obese (Stein et al., 2016) . This is likely due to the increased prevalence of the subclinical and potential forms of CD observed in adulthood (Fasano and Catassi, 2001) . A significant portion of children newly diagnosed with CD have also been shown to be overweight or obese (Reilly et al., 2011; Venkatasubramani et al., 2010) . Interestingly, adherence to a gluten-free diet in both overweight or obese children and adults with CD has been shown to result in beneficial decreases in BMI (Cheng et al., 2010; Reilly et al., 2011) . Our results support the notion that many adults with undiagnosed CD may not be underweight. Taken together with evidence which suggests it may take longer for overweight individuals to receive a diagnosis of CD (Tucker et al., 2012) , this illustrates why the possibility of CD should not be overlooked in overweight and obese individuals with signs and symptoms consistent with CD.
We observed significant differences in lipid profiles in those with positive CD serology compared with those with negative serology. In agreement with previous findings, we observed lower levels of both HDL-cholesterol and apo-AI in individuals with positive CD serology (Capristo et al., 2000) . We did not observe lower total cholesterol values in individuals with positive CD serology reported in some studies of patients with newly diagnosed CD (Ciacci et al., 1999; Lewis et al., 2009; West et al., 2003) . However, recent studies suggest that such changes in total cholesterol in CD may be largely driven by HDL-cholesterol (Brar et al., 2006) . It is possible that changes in the intestinal mucosa associated with CD could lead to reduced lipid absorption and lower levels of HDL-cholesterol. The link between apo-AI and the intestinal mucosa could further explain the unique association with HDL-cholesterol. Apo-AI is produced and secreted in the intestinal mucosa, and CD-associated damage to the mucosa has been shown to lead to a reduction in apo-AI levels (Capristo et al., 2000; Floren and Alm, 1988) . Apo-AI is the major lipoprotein constituent of HDL-cholesterol (Frank and Marcel, 2000) , and a decrease in apo-AI levels would lead to a reduction in HDL-cholesterol synthesis. In support of this proposed mechanism, we observed that individuals with positive CD serology had significantly lower levels of apo-AI and a higher apo-B/AI ratio compared with those with negative serology. Alternatively, HDL-cholesterol and apo-AI are known negative acute phase reactants (Khovidhunkit et al., 2000 (Khovidhunkit et al., , 2004 , and it is possible that inflammation in the intestinal mucosa in individuals with positive CD serology could have contributed to this observation. However, serum concentrations of C-reactive protein were not elevated in individuals with positive CD serology in the present study, suggesting the lack of a substantial acute phase response in such individuals. Regardless of the mechanism, a recent meta-analysis found that individuals with CD are at a greater risk for cardiovascular disease (CVD) than the general population (Emilsson et al., 2015) . Our findings of lower HDL-cholesterol and apo-AI, and a higher ratio of total to HDL-cholesterol and apo-B/apo-AI in individuals with positive CD serology are consistent with recent data from patients with newly diagnosed CD (Tetzlaff et al., 2017) , and suggest that unfavorable lipid profiles prior to CD diagnosis may explain a portion of this increased risk of CVD. Considering that adherence to a gluten-free diet has been shown to increase levels of HDL-cholesterol as well as decrease the ratio of total to HDL-cholesterol in newly diagnosed individuals (Brar et al., 2006; De Marchi et al., 2013; Lewis et al., 2009) , this highlights the importance of timely diagnosis and treatment with a gluten-free diet in individuals with CD. We observed significantly lower levels of retinol in individuals with positive CD serology. Although short-term dietary intake generally has little influence on circulating retinol levels, this association remained significant after adjustment for dietary intake of vitamin A (retinol activity equivalents) and there was no significant difference in intake of retinol between those with positive and negative CD serology (p>0.05). This suggests that differences in retinol intake do not explain the observed difference in circulating levels. Lower levels of serum retinol and a higher prevalence of retinol deficiency have been previously reported in individuals with CD (Wierdsma et al., 2013) . Although no individuals with positive CD serology were retinol deficient (<0.70 mmol/l) (Sommer et al., 2002) in the present study, our results suggest the possibility of maldigestion and malabsorption of certain lipid-soluble compounds in individuals with undiagnosed CD. However, it must be noted that maldigestion and malabsorption were not explicitly assessed in the present study. We also identified an association between positive CD serology and lower levels of circulating 25OHD in unadjusted models; however, this association was attenuated in fully adjusted models. Nevertheless, lower levels of serum vitamin D have been previously reported in individuals with untreated CD (Corazza et al., 1996; Kemppainen et al., 1999) . This could be due to malabsorption or a consequence of either reduced sun exposure or lower intake of vitamin D from dietary sources, which is particularly possible in CD considering the high prevalence of secondary lactose intolerance (Bode and Gudmand-Hoyer, 1988 ).
We did not observe differences in various tocopherols or carotenoids in individuals with positive CD serology. Furthermore, individuals with positive CD serology did not have markedly lower levels of most biomarkers of nutritional status assessed. We also observed no significant increase in C-reactive protein, a marker of systemic inflammation, in those with positive CD serology as previously reported in some diagnosed cases of CD (Bayar et al., 2016; De Marchi et al., 2013; Tetzlaff et al., 2017) . This suggests that individuals with positive CD serology identified through screening studies may not present with widespread nutrient deficiencies or elevated markers of systemic inflammation. Indeed, cases of CD diagnosed in adulthood are more likely to be of the non-classical, subclinical, and potential presentations (Guandalini and Assiri, 2014) . It also stands to reason that those with undiagnosed CD would be more likely to present with milder symptoms than those who ultimately seek medical attention that leads to a diagnosis. Individuals in the present study population with potential undiagnosed CD may be particularly likely to represent mild cases of CD. Both studies had a certain degree of participant burden and it is possible that individuals with increasingly symptomatic forms of undiagnosed CD would avoid participation in such studies. Nevertheless, while the lack of mucosal biopsies in the present study precludes the assessment of CD severity, these findings suggest that many cases of undiagnosed CD identified through screening may not present with elevated markers of inflammation or nutrient deficiencies. This represents an important consideration when assessing the benefits and drawbacks to population screening for CD. The present study has some limitations. Although the total number of individuals in the study was relatively large, the number of individuals with positive CD serology was limited. This likely resulted in reduced statistical power to detect associations with the various biomarkers analyzed. Moreover, biomarkers of nutritional status were only available for a limited subset of participants from the initial study population. Biopsy samples were not available for individuals with positive CD serology and definitive diagnoses of CD can therefore not be made. Furthermore, serum values for select vitamins and minerals in which individuals with CD are commonly deficient, including vitamin B 12 and iron (Dahele and Ghosh, 2001; Halfdanarson et al., 2007) , were not available in our study populations. Adherence to a gluten-free diet could have led to false negative serological findings; however, a very limited number of subjects (n¼10) without a diagnosis of CD reported following a gluten-free/reduced diet. This would only result in a higher prevalence of undiagnosed cases. Alternatively, it is possible that other autoimmune or liver conditions could lead to false positive tTG serological findings. However, there were no notable self-reported autoimmune or liver disorders among those with positive CD serology. Two individuals with positive CD serology reported arthritis, but this has been previously described as an extra-intestinal manifestation of CD (Barton and Murray, 2008; Lubrano et al., 1996) . Finally, although the analyses were adjusted for a number of potential confounders, the observed associations could be influenced by residual confounding and causality cannot be inferred due to the cross-sectional nature of the study.
In summary, we assessed various biomarkers of health and nutritional status in those with positive CD serology identified through a screening study of Canadian adults. Individuals with positive CD serology but no diagnosis of CD had lower levels of HDL-cholesterol, apo-AI, and a higher ratio of total to HDL-cholesterol and apo-B/apo-AI. Compared to individuals with negative CD serology, individuals with likely undiagnosed CD also had lower circulating levels of retinol. These results suggest that undiagnosed cases of CD identified through screening may be associated with altered lipid profiles and lower levels of certain fat-soluble vitamins. However, severe nutrient deficiencies were not evident in individuals with positive CD serology, suggesting more mild manifestations of CD in such cases.
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